A Long, Strange Trip: 510(k) Reform At One Year

02 Jan 2012

A rundown by “The Gray Sheet” of the most significant 510(k) reform actions taken in 2011, what’s on deck for 2012 and what reform will mean to device makers in the near term.

A year into FDA’s comprehensive 510(k) reform plan, at least one thing is apparent: FDA is setting a new personal best, releasing scores of new guidance documents, standard operating procedures, pilot programs and other initiatives at a breakneck pace.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Switzerland Investigates Private Sector Assessment of FDA-Approved Medical Devices

01 May 2025

• By Amanda Maxwell

Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.

Medtech Seeks Inclusion In EU’s Groundbreaking Life Sciences Strategy

29 Apr 2025

• By Amanda Maxwell

As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

24 Apr 2025

• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.